Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma

BACKGROUND: Cholangiocarcinoma is an aggressive tumor with poor prognosis. Most of the cases are not available for surgery at the stage of the diagnosis and the best clinical practice chemotherapy results in about 12-month median survival. Several tyrosine kinase inhibitors (TKIs) are currently unde...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Exp Hematol Oncol
Egile Nagusiak: Poddubskaya, Elena V., Baranova, Madina P., Allina, Daria O., Smirnov, Philipp Y., Albert, Eugene A., Kirilchev, Alexey P., Aleshin, Alexey A., Sekacheva, Marina I., Suntsova, Maria V.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2018
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6127913/
https://ncbi.nlm.nih.gov/pubmed/30202637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0113-x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak